Evidence map›Paper›PMID 40962378›Full record

ReviewJournal of the American College of Cardiology2025

Outcomes and Management of Stressor-Associated Atrial Fibrillation: JACC State-of-the-Art Review.

Julian S Haimovich, Shinwan Kany, Ezimamaka Ajufo, Jason G Andrade, Emelia J Benjamin, Jeffrey S Healey, Paulus Kirchhof, Steven A Lubitz, William F McIntyre, Michiel Rienstra and 4 more

Abstract readReview
In one paragraph

Review in Journal of the American College of Cardiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Julian S HaimovichCardiovascular Disease Initiative, The Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA; Cardiovascular Research Center, Massachusetts General Hospital, Boston, Massachusetts, USA; Cardiology Division, Massachusetts General Hospital, Boston, Massachusetts, USA.
Shinwan KanyCardiovascular Disease Initiative, The Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA; Department of Cardiology, University Heart and Vascular Center Hamburg-Eppendorf, Hamburg, Germany; German Center for Cardiovascular Research, Partner Site Hamburg/Kiel/Lübeck, Hamburg, Germany.
Ezimamaka AjufoCardiovascular Disease Initiative, The Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA; Cardiology Division, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Jason G AndradeInstitut de Cardiologie de Montreal, Université de Montréal, Montreal, Quebec, Canada; University of British Columbia, Vancouver, British Columbia, Canada.
Emelia J BenjaminBoston University and National Heart, Lung, Blood Institute's Framingham Heart Study, Framingham, Massachusetts, USA; Section of Cardiovascular Medicine, Department of Medicine, Boston Medical Center, Boston, Massachusetts, USA; Chobanian and Avedisian School of Medicine, Boston University, Boston, Massachusetts, USA; Boston University School of Public Health, Boston, Massachusetts, USA.
Jeffrey S HealeyPopulation Health Research Institute, McMaster University, Hamilton, Ontario, Canada.
Paulus KirchhofDepartment of Cardiology, University Heart and Vascular Center Hamburg-Eppendorf, Hamburg, Germany; German Center for Cardiovascular Research, Partner Site Hamburg/Kiel/Lübeck, Hamburg, Germany.
Steven A LubitzTelemachus and Irene Demoulas Family Foundation Center for Cardiac Arrhythmias, Massachusetts General Hospital, Boston, Massachusetts, USA.
William F McIntyrePopulation Health Research Institute, McMaster University, Hamilton, Ontario, Canada.
Michiel RienstraDepartment of Cardiology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
Prashanthan SandersCentre for Heart Rhythm Disorders, Royal Adelaide Hospital, University of Adelaide, Adelaide, South Australia, Australia.
Renate B SchnabelDepartment of Cardiology, University Heart and Vascular Center Hamburg-Eppendorf, Hamburg, Germany; German Center for Cardiovascular Research, Partner Site Hamburg/Kiel/Lübeck, Hamburg, Germany.
Patrick T EllinorCardiovascular Disease Initiative, The Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA; Cardiovascular Research Center, Massachusetts General Hospital, Boston, Massachusetts, USA; Telemachus and Irene Demoulas Family Foundation Center for Cardiac Arrhythmias, Massachusetts General Hospital, Boston, Massachusetts, USA.
Shaan KhurshidCardiovascular Disease Initiative, The Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA; Cardiovascular Research Center, Massachusetts General Hospital, Boston, Massachusetts, USA; Telemachus and Irene Demoulas Family Foundation Center for Cardiac Arrhythmias, Massachusetts General Hospital, Boston, Massachusetts, USA. Electronic address: skhurshid@mgb.org.

Funding

IDENTIFICATION OF COMMON GENETIC VARIANTS FOR ATRIAL FIBRILLATION AND PR INTERVALR01HL092577 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI BENJAMIN, EMELIA J., ELLINOR, PATRICK THOMAS · 2009 to 2025
$20.6M
ConProject-006U54HL120163 · NHLBI · AMERICAN HEART ASSOCIATION · PI BHATNAGAR, ARUNI, ROBERTSON, ROSE MARIE · 2018 to 2022
$18.8M
MULTIDISCIPLINARY RESEARCH TRAINING IN CARDIOLOGYT32HL007208 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI Patrick Thomas Ellinor, David E Sosnovik · 1985 to 2026
$16.1M
PRROPS: Pathways of Risk and Resilience for Overlapping Pain and SensitizationR01NS121419 · NINDS · BOSTON UNIVERSITY MEDICAL CAMPUS · PI Emelia J. Benjamin, ROBERT R EDWARDS · 2021 to 2026
$3.7M
CAPSITE: Community Assessment of Pain and Sensitization in the ElderlyR01AG066010 · NIA · BOSTON UNIVERSITY MEDICAL CAMPUS · PI BENJAMIN, EMELIA J., EDWARDS, ROBERT R · 2020 to 2025
$3.3M
Pain in community-based older African American Adults: The Jackson Heart StudyR01AG066914 · NIA · BOSTON UNIVERSITY MEDICAL CAMPUS · PI BENJAMIN, EMELIA J., EDWARDS, ROBERT R · 2020 to 2024
$3.2M
Using Electrocardiogram Genetics to Inform Arrhythmia RiskR01HL157635 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI ELLINOR, PATRICK THOMAS, MIRSHAHI, TOORAJ · 2022 to 2025
$2.9M
FHS-NEXT - Framingham Novel EXam using TechnologyR01HL141434 · NHLBI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI BENJAMIN, EMELIA J., MCMANUS, DAVID D. · 2019 to 2022
$2.5M
From genetic basis to mechanisms for Heart FailureR01HL177209 · NHLBI · BROAD INSTITUTE, INC. · PI Patrick Thomas Ellinor, Ling Xiao · 2025 to 2026
$1.6M
Electrocardiogram-based deep learning and decision analysis to improve atrial fibrillation risk estimationK23HL169839 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI Shaan Khurshid · 2023 to 2026
$860k
American Heart Association-American Stroke Association 23CDA1050571NHLBI NIH HHS K23 HL169839NHLBI NIH HHS R01 HL092577NHLBI NIH HHS R01 HL141434NHLBI NIH HHS R01 HL157635NHLBI NIH HHS R01 HL177209NHLBI NIH HHS T32 HL007208NHLBI NIH HHS U54 HL120163NIA NIH HHS R01 AG066010NIA NIH HHS R01 AG066914NINDS NIH HHS R01 NS121419
6 · The paper itself

Abstract

Stressor-associated atrial fibrillation (AF) is defined as new onset AF occurring in the setting of an acute and reversible physiologic stressor (eg, cardiac surgery, acute infection). Although historically viewed as transient and potentially benign, a growing body of evidence demonstrates that stressor-associated AF is prognostically important, with long-term rates of AF recurrence and AF-related adverse events (eg, stroke, heart failure) approaching those of AF occurring without a stressor. Nevertheless, key aspects of stressor-associated AF management (eg, prevention, surveillance, treatment) remain highly variable. In this state-of-the-art review, we provide a clinically oriented synthesis of the epidemiology, mechanisms, outcomes, and management of stressor-associated AF across the breadth of characterized precipitants. Within this context, we outline a pathophysiologic framework in which stressor-associated AF represents a spectrum spanning variable relative contributions of direct stressor effects, stressor-mediated substrate, and underlying predisposition (ie, modifiable and nonmodifiable AF risk factors). Stressor-associated AF episodes occurring in the setting of a strong underlying predisposition to AF (sometimes termed "provoked AF") have a higher risk of recurrence, while episodes occurring in response to a profound physiologic stressor with minimal or no underlying predisposition (sometimes termed "reversible AF") have a lower risk of recurrence. Using postcardiac surgery stressor-associated AF as an exemplar, we summarize recent advances translating greater pathophysiologic understanding (eg, role of local inflammation) into novel clinical interventions capable of reducing stressor-associated AF incidence (eg, posterior pericardiotomy). We summarize available evidence for clinical management of stressor-associated AF and offer a conceptual framework to inform care. Finally, we conclude by outlining key priorities for future research designed to facilitate precision management of stressor-associated AF, including identification of more effective preventive measures, development of models to stratify risk of recurrent AF and AF-related adverse events following a stressor-associated AF episode, and integration of patient-centered outcomes.

Indexed as

Atrial FibrillationDisease ManagementStress, PhysiologicalStress, PsychologicalHumansRisk Factorsmanagementoutcomespathophysiologyreviewtriggered atrial fibrillation

Identifiers

PMID40962378
PMCPMC13675867

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.